reports hero background
UPDATED: Nov 10, 2025

Stock Analysis

PFE Logo
Pfizer
NYSE:PFE
$24.43
$0.01 |0.04%
Day Range:
$24.11 - $24.63
Market Cap:
139.80B
P/E Ratio:
14.2035
Avg Value:
$24.30
Year Range:
$20.92 - $27.69
1
General Information
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion.

While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.

2
Pfizer (PFE) Stock Graph
3
How We Grade Pfizer (PFE)

We grade stocks based on past performance, their future growth potential, intrinsic value, dividend history, and overall financial health.

The chart below shows how we grade Pfizer (PFE) across the board compared to its closest peers.

4
Benzinga Edge Rankings

Benzinga Edge stock rankings give you four critical scores to help you identify the strongest and weakest stocks to buy and sell.

13.52

Growth measures a stock's combined historical expansion in earnings and revenue across multiple time periods, with emphasis on both long-term trends and recent performance.

29.07

Value is a percentile-ranked composite metric that evaluates a stock's relative worth by comparing its market price to fundamental measures of the company's assets, earnings, sales, and operating performance.

Momentum measures a stock's relative strength based on its price movement patterns and volatility over multiple timeframes, ranked as a percentile against other stocks.

Quality is a composite ranking that evaluates a company's operational efficiency and financial health by analyzing historical profitability metrics and fundamental strength indicators on a percentile basis relative to peers.

Stock Score Locked: Want to See it?
Benzinga Rankings give you vital metrics on any stock – anytime.
5
Peer Ratings

See how Pfizer compares to its peers in these key performance metrics from Benzinga Rankings.

Top Peers
Value
Quality
Growth
Momentum
Short
Medium
Long
SNYSanofi
18.68
0
75.13
32.95
BMYBristol-Myers Squibb
30.37
23.93
58.34
25.71
GSKGSK
27.8
50.74
46.16
79.47
NVONovo Nordisk
27.14
53.8
43.88
6.67
Short: price trend over the last couple of months
Medium: price trend over the last couple of quarters
Long: price trend over the past year
Stock Score Locked: Want to See it?
Benzinga Rankings give you vital metrics on any stock – anytime.
6
Valuation

Earnings History (3 years)

It is important to look at a companies earnings history to see not only if they are profitable, but if their earnings are growing.
As you can see from the chart above, PFE's earnings have fluctuated but has increased since, this is a positive sign for the stock.
7
Financial Health
What is the current state of the company's financial situation?

We measure the health of a company based on how profitable they are and their ability to cover both their short-term and long-term debts. The key indicators that we use are the Operating Margin, Quick Ratio, and Debt-to-Equity ratio relative to the companies peers

Operational Margin 0.2484

The operating margin measures how much profit a company makes after it spends money on wages, materials or other administrative expenses but before interest and taxes. It is a good representation of how efficiently a company is able to generate profit from its core operations.

Quick Ratio 0.9044

The quick ratio measures how much of a company's debt, that is due in less than 1 year, can be covered using its cash equivalents, marketable securities, and money that is currently owed to them (accounts receivables).

A company with a quick ratio of less than 1.00 does not, in many cases, have the capital on hand to meet its short-term obligations if they were all due at once, while a quick ratio greater than one indicates the company has the financial resources to remain solvent in the short term.

Debt-to-Equity 1.2461

Debt-to-equity is calculated by dividing a company's total liabilities by its shareholders equity. It is a measure of the degree to which a company is financing its operations through debt versus wholly owned funds. Generally speaking, a D/E ratio below 1.0 would be seen as relatively safe, whereas ratios of 2.0 or higher would be considered risky.

The chart above shows Pfizer (PFE) operating margin, quick ratio, and debt-to-equity ratio compared to its peers. The black markers represent the peer averages for each ratio and the blue bars represent Pfizer (PFE) ratio values.
8
Dividend
There are few things we like to see when evaluating the quality of a company's dividend history and future

Ideally, we would like to see a company have a long history of consistently high dividend payouts that have grown at a consistent rate. From here we want to be confident that this sort of dividend growth and consistency will persist into the future.

The chart below shows the historical trend in Pfizer (PFE) dividend yield on an annual basis.

79.17%
Pfizer (PFE) saw a increase in it's dividend yield since 2020
9
Past Performance
How has Pfizer (PFE) performed over the past 5 years?

The two main factors that we consider when analyzing past performance is overall return and volatility

Using these two metrics, we can determine if this stock gave its investors enough return for the risk that they took on by owning it. This is measured by the sharpe ratio, which has been used as a primary measure of risk/reward trade-off for almost 60 years.

This ratio can be interpreted as the amount of return an investor has received for the amount of risk that they took on by owning the stock over that timeframe.

Pfizer (PFE) sharpe ratio over the past 5 years is -0.8873 which is considered to be below average compared to the peer average of 0.4940

10
Analyzing Pfizer (PFE) Recent Options Activity
Below, you can see the trend in options sentiment over the past 30 days.

Based on our data, PFE's options trades have recently carried more negative sentiment than positive.

11
Company Financials
INCOME STATEMENT
The income statement also known as the profit and loss statement, primarily focuses on the company's revenues and expenses during a particular period.

The main purpose of an income statement is to convey details of profitability and business activities. Below, is PFE's income statement for the previous four years along with its trailing-twelve- month profit & loss.

FISCAL YEAR (BIL.)
2021 ($)
2022 ($)
2023 ($)
2024 ($)
TTM ($)
Total Revenue
81.29
100.33
58.50
63.63
62.79
Operating Revenue
81.29
100.33
58.50
63.63
62.79
Cost Of Revenue
30.82
34.34
24.96
17.85
16.70
Gross Profit
50.47
65.99
33.54
45.78
46.08
Operating Expense
30.23
29.67
30.38
30.95
30.66
Selling General And Administration
12.70
13.68
14.77
14.73
13.91
Research and Development
13.83
12.38
10.87
10.93
11.76
Operating Income
20.23
36.32
3.17
14.83
15.42
Net Non-Operating Interest Income Expense
-1.25
-0.99
-0.58
-2.54
-2.09
Other Income Expense
5.33
-0.60
-1.52
-4.26
-4.17
Other Non-Operating Income Expenses
4.46
2.02
2.25
0.16
0.28
Pre-Tax Income
24.31
34.73
1.06
8.02
9.15
Tax Provision
1.85
3.33
-1.11
-0.03
-0.69
Net Income
21.98
31.37
2.12
8.03
9.83
Net Income Common Stockholders
21.98
31.37
2.12
8.03
9.83
Total Operating Income As Reported
0.00
0.00
0.00
0.00
0.00
Total Expenses
61.05
64.01
55.33
48.80
47.37
Net Income From Continuing And Discontinued Operation
21.98
31.37
2.12
8.03
9.83
Normalized Income
22.05
34.14
5.58
11.67
13.38
Interest Income
0.04
0.25
1.62
0.55
0.61
Interest Expense
1.29
1.24
2.21
3.09
2.70
Net Interest Income
-1.25
-0.99
-0.58
-2.54
-2.09
EBIT
25.60
35.97
3.27
11.11
11.85
EBITDA
30.80
41.03
9.56
18.13
18.55
Reconciled Cost Of Revenue
29.33
32.89
23.40
16.12
15.01
Reconciled Depreciation
5.19
5.06
6.29
7.01
6.70
Normalized EBITDA
30.40
44.09
13.83
22.65
23.00
Tax Rate For Calcs
0.00
0.00
0.00
0.00
0.21
Tax Effect Of Unusual Items
0.04
-0.28
-0.83
-0.87
-0.87
BALANCE SHEET
The balance sheet is a snapshot of a companies financials during a particular period in time.

It breaks down what company owns (assets) and what a company owes (liabilities), in order to give investors an overview of its capital structure.

FISCAL YEAR (BIL.)
2021 ($)
2022 ($)
2023 ($)
2024 ($)
TTM ($)
Total Assets
181.48
197.21
226.50
213.40
208.73
Current Assets
59.69
51.26
43.33
50.36
46.92
Total Non-Current Assets
121.78
145.94
183.17
163.04
161.81
Total Liabilities Net Minority Interest
104.01
101.29
137.21
124.90
115.64
Current Liabilities
42.67
42.14
47.79
42.99
36.60
Other Non-Current Liabilities
9.74
13.18
16.54
14.15
13.61
Total Equity Gross Minority Interest
77.46
95.92
89.29
88.50
93.10
Stockholders Equity
0.00
0.00
0.00
0.00
0.00
Total Capitalization
111.96
127.59
149.51
144.91
149.35
Common Stock Equity
77.20
95.66
89.01
88.20
92.80
Net Tangible Assets
2.85
0.92
-43.67
-35.74
-27.62
Working Capital
17.02
9.12
-4.46
7.36
10.33
Invested Capital
114.20
130.53
159.86
151.85
153.65
Tangible Book Value
2.85
0.92
-43.67
-35.74
-27.62
Total Debt
37.00
34.87
70.84
63.65
60.85
Net Debt
35.05
34.45
67.99
62.61
59.51
Share Issued
9.47
9.52
9.56
9.59
9.62
Ordinary Shares Number
5.62
5.62
5.65
5.67
5.69
CASH FLOW STATEMENTS
A companies statement of cash flows gives an investor a break down of the cash inflows and outflows from a companies operations and investment activities.
FISCAL YEAR (BIL.)
2021 ($)
2022 ($)
2023 ($)
2024 ($)
TTM ($)
Cash Flow from Continuing Operating Activities
32.92
29.27
8.70
12.74
13.07
Net Income from Continuing Operations
22.46
31.40
2.17
8.05
9.84
Depreciation and Amortization
5.19
5.06
6.29
7.01
6.70
Deferred Tax
-4.29
-3.76
-3.44
-2.10
-2.10
Deferred Income Tax
-4.29
-3.76
-3.44
-2.10
-2.10
Stock-Based Compensation
1.18
0.87
0.53
0.88
0.75
Other Non-Cash Items
-4.70
-0.40
-4.28
-2.27
-2.12
Change in Working Capital
12.80
-4.46
-2.17
-3.07
-4.02
Change in Receivables
Changes in Account Receivables
Change in Inventory
Change in Payables and Accrued Expense
Change in Payable
Change in Account Payable
Change in Other Current Assets
Change in Other Current Liabilities
Change in Other Working Capital
Cash Flow from Continuing Investing Activities
-22.53
-15.78
-32.28
2.65
3.17
Net PPE Purchase and Sale
-2.71
-3.24
-3.91
-2.91
-2.70
Net Business Purchase and Sale
-23.00
-43.43
7.04
9.86
Purchase of Business
-23.00
-43.43
Net Investment Purchase and Sale
-19.52
6.68
15.24
-1.48
-4.30
Purchase of Investment
-47.61
-38.78
-31.18
-10.31
-20.05
Sale of Investment
28.10
45.46
46.42
8.83
15.75
Net Other Investing Changes
-0.31
-0.19
-0.18
Financing Cash Flow
-9.82
-14.83
26.07
-17.14
-16.01
Cash Flow from Continuing Financing Activities
-9.82
-14.83
26.07
-17.14
-16.01
Net Issuance Payments of Debt
-1.10
-3.52
35.95
-7.16
-5.88
Net Long-Term Debt Issuance
-1.01
-3.30
28.26
-2.25
-0.06
Long-Term Debt Issuance
1.00
Long-Term Debt Payments
-2.00
-3.30
-2.57
-2.25
-3.75
Net Short-Term Debt Issuance
-0.10
-0.22
7.68
-4.91
-5.82
Net Common Stock Issuance
-2.00
Common Stock Issuance
Common Stock Payments
-2.00
Cash Dividends Paid
-8.73
-8.98
-9.25
-9.51
-9.71
Net Other Financing Charges
0.02
-0.33
-0.63
-0.47
-0.43
End Cash Position
8.24
6.14
11.07
4.16
5.68
Changes in Cash
0.22
-1.35
2.49
-1.74
0.23
Beginning Cash Position
8.09
7.66
8.62
5.97
5.43
Capital Expenditure
-2.71
-3.24
-3.91
-2.91
-2.70
Issuance of Capital Stock
Issuance of Debt
1.00
38.52
8.91
4.42
Repayment of Debt
-2.10
-7.41
-2.57
-16.07
-10.30
Repurchase of Capital Stock
-2.00
Free Cash Flow
29.87
26.03
4.79
9.84
10.38